Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

418

Participants

Timeline

Start Date

May 14, 2024

Primary Completion Date

June 17, 2025

Study Completion Date

June 17, 2026

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Sonelokimab

Sonelokimab

DRUG

Placebo

Placebo

Trial Locations (106)

1200

Clinical Site, Woluwe-Saint-Lambert

1431

Clinical Site, Sofia

1463

Clinical Site, Sofia

1510

Clinical Site, Sofia

1606

Clinical Site, Sofia

3000

Clinical Site, Leuven

4000

Clinical Site, Liège

6003

Clinical Site, Stara Zagora

9000

Clinical Site, Ghent

10003

Clinical Site, New York

10117

Clinical Site, Berlin

11009

Clinical Site, Cadiz

14004

Clinical Site, Córdoba

15006

Clinical Site, Prague

15706

Clinical Site, Santiago de Compostela

18012

Clinical Site, Granada

18014

Clinical Site, Granada

20246

Clinical Site, Hamburg

21000

Clinical Site, Dijon

21287

Clinical Site, Baltimore

23538

Clinical Site, Lübeck

24105

Clinical Site, Kiel

25030

Clinical Site, Besançon

26505

Clinical Site, Morgantown

28006

Clinical Site, Madrid

28007

Clinical Site, Madrid

28041

Clinical Site, Madrid

28046

Clinical Site, Madrid

28922

Clinical Site, Alcorcón

29010

Clinical Site, Málaga

29200

Clinical SIte, Brest

31400

Clinical Site, Toulouse

33012

Clinical Site, Hialeah

33136

Clinical Site, Miami

33180

Clinical Site, Aventura

33613

Clinical Site, Tampa

33647

Clinical Site, Bielefeld

34295

Clinical Site, Montpellier

34470

Clinical Site, Ocala

35244

Clinical Site, Birmingham

37130

Clinical Site, Murfreesboro

41009

Clinical Site, Seville

42071

Clinical Site, Murray

42270

Clinical Site, Saint-Priest-en-Jarez

43213

Clinical Site, Columbus

44791

Clinical Site, Bochum

46014

Clinical Site, Valencia

46026

Clinical Site, Valencia

46168

Clinical Site, Plainfield

46940

Clinical Site, Manises

48187

Clinical Site, Canton

48328

Clinical Site, Waterford

48346

Clinical Site, Clarkston

48455

Clinical Site, Bad Bentheim

49565

Clinical Site, Bramsche

50566

Clinical Site, Wroclaw

53226

Clinical Site, Milwaukee

55112

Clinical Site, New Brighton

58103

Clinical Site, Fargo

60077

Clinical Site, Skokie

64283

Clinical Site, Darmstadt

68144

Clinical Site, Omaha

69003

Clinical Site, Lyon

70809

Clinical Site, Baton Rouge

72037

Clinical Site, Le Mans

72117

Clinical Site, North Little Rock

75025

Clinical Site, Plano

76031

Clinical Site, Rouen

78213

Clinical Site, San Antonio

86179

Clinical Site, Augsburg

89145

Clinical Site, Las Vegas

90404

Clinical Site, Santa Monica

91702

Clinical Site, Trnava

92160

Clinical Site, Antony

92708

Clinical Site, Fountain Valley

94160

Clinical Site, Saint-Mandé

97080

Clinical Site, Würzburg

48109-5314

Clinical Site, Ann Arbor

75390-8565

Clinical Site, Dallas

T3E 0B2

Clinical Site, Calgary

T6G 1C3

Clinical Site, Edmonton

N1L 0B7

Clinical Site, Guelph

K9J 5K2

Clinical Site, Peterborough

L4B 1A5

Clinical Site, Richmond Hill

M4E 1R7

Clinical Site, Toronto

N8W 1E6

Clinical Site, Windsor

S7K 2C1

Clinical Site, Saskatoon

708 52

Clinical Site, Ostrava

110 00

Clinical Site, Prague

01307

Clinical Site, Dresden

07548

Clinical Site, Gera

D04 T6F4

Clinical Site, Dublin

3015 GD

Clinical Site, Rotterdam

41-500

Clinical Site, Chorzów

40-611

Clinical Site, Katowice

25-316

Clinical Site, Kielce

10-229

Clinical Site, Olsztyn

61-731

Clinical Site, Poznan

70-332

Clinical Site, Szczecin

02-953

Clinical Site, Warsaw

03010

Clinical Site, Alicante

08916

Clinical Site, Badalona

08003

Clinical Site, Barcelona

08036

Clinical Site, Barcelona

08041

Clinical Site, Barcelona

08402

Clinical Site, Granollers

Sponsors
All Listed Sponsors
lead

MoonLake Immunotherapeutics AG

INDUSTRY

NCT06411379 - Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter